scholarly journals Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib

2021 ◽  
pp. 100393
Author(s):  
Dylan J. Martini ◽  
Meredith R. Kline ◽  
Yuan Liu ◽  
Julie M. Shabto ◽  
Bradley C. Carthon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Scoring System ◽  
Risk Scoring ◽  
Risk Scoring System

Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C).

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 734-734
Author(s):  
Meredith R Kline ◽  
Dylan J. Martini ◽  
Yuan Liu ◽  
Julie M. Shabto ◽  
Bradley Curtis Carthon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Scoring System ◽  
Group Performance ◽  
Eastern Cooperative Oncology Group ◽  
Risk Scoring ◽  
Ecog Ps ◽  
Risk Scoring System

734 Background: Cabozantinib (C) is an effective treatment for metastatic renal cell carcinoma (mRCC) patients (pts). The international mRCC database consortium (IMDC) criteria is the gold standard for mRCC risk stratification. We created a risk scoring system for mRCC pts treated with C. Methods: We performed a retrospective review of 87 mRCC pts treated with C at Winship Cancer Institute from 2015-19. Overall survival (OS) and progression free survival (PFS) were defined as months from C initiation. The baseline characteristics and inflammation biomarkers included were monocyte, neutrophil, and platelet-to-lymphocyte ratios (MLR, NLR, and PLR respectively), RCC histology, body mass index (BMI), metastatic sites (mets), and Eastern Cooperative Oncology Group performance status (ECOG PS). Upon variable selection in multivariable analysis (MVA), elevated baseline MLR (≥0.71), presence of sarcomatoid histology, ECOG PS > 1, and absence of bone metastases were assigned 1 point. A three-level risk scoring system was created: low (score = 0-1), intermediate (score = 2), and high risk (score = 3-4). The Kaplan-Meier method, Cox proportional hazard model, and Uno’s C-statistics were used to examine performance. Results: The majority of pts were males (71%) with clear-cell RCC (75%). Most pts (67%) received 1+ prior line of therapy. High and intermediate risk pts had significantly shorter OS and PFS compared to low risk pts (Table). The C-statistics for our risk scoring system were higher than IMDC in predicting OS (0.7 vs. 0.62) and PFS (0.65 vs 0.57). Conclusions: Pts treated with C may benefit from risk scoring using RCC histology, ECOG PS, mets, and MLR. These results are hypothesis-generating and should be validated in a larger study.[Table: see text]

1103: Laparoscopic Salvage Nephrectomy after Targeted Neoadjuvant Therapy for Metastatic Renal Cell Carcinoma: Initial Results

2007 ◽  
Vol 177 (4S) ◽  
pp. 364-364 ◽  
Author(s):  
Surena F. Matin ◽  
Christopher G. Wood ◽  
Shi-Ming Tu ◽  
Nizar M. Tannir ◽  
Eric Jonasch
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neoadjuvant Therapy ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Initial Results

637: Establishing a Porcine Model for the Accelerated Development of Cancer Vaccines for Patients with Metastatic Renal Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 173-174
Author(s):  
Quinton V. Cancel ◽  
Benjamin K. Yang ◽  
Zhen Su ◽  
Jens Dannull ◽  
Philipp Dahm ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cancer Vaccines ◽  
Porcine Model

1716: Pharmaco-Angio-CT is Superior to 4 Phase Helical CT in the Detection of Recurrent Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 551-552
Author(s):  
Erich K. Lang ◽  
Richard J. Macchia ◽  
Raju Thomas ◽  
Ronald Davis ◽  
Douglas Slakey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Helical Ct ◽  
Angio Ct

396: HSP27 Expression in Primary and Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 129-129
Author(s):  
Richard E. Zigeuner ◽  
Nikolaus Droschl ◽  
Volkmar Tauber ◽  
Peter Rehak ◽  
Cord Langner
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Hsp27 Expression

392: Osteopontin Expression in Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 128-128
Author(s):  
Adrienne J.K. Carmack ◽  
Daniel Saenz ◽  
Merce Jorda ◽  
Thomas Temple ◽  
Balakrishna L. Lokeshwar
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Osteopontin Expression
Sign in / Sign up

Export Citation Format

Share Document